H-Index
10
Scimago Lab
powered by Scopus
eISSN: 2325-4416
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
AmJCaseRep

Annals
ISI-Home

Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China

Zhixiong Zhong, Jingyuan Hou, Bing Li, Qifeng Zhang, Sudong Liu, Cunren Li, Zhidong Liu, Min Yang, Wei Zhong, Pingsen Zhao

Center for Cardiovascular Diseases, Meizhou People’s Hospital, Huangtang Hospital, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, Guangdong, China (mainland)

Med Sci Monit 2017; 23:6186-6192

DOI: 10.12659/MSM.905337

Available online:

Published: 2017-12-30


BACKGROUND: Cytochrome P450 (CYP) 2C19 is an enzyme involved in the bioactivation of various important therapeutic drugs, from pro-drugs to an active inhibitor of platelet action. Variants in the CYP2C19 gene influence the pharmacokinetics and clinical response to antiplatelet drugs such as clopidogrel; however, there is no available data about the genetic variation of CYP2C19 in the Hakka population in China.
MATERIAL AND METHODS: A total of 6686 unrelated participants (ages 17–98 years) of self-reported Hakka ancestry admitted at an inpatient department in a hospital in southern China were successfully genotyped by the gene chip platform.
RESULTS: The identified allele frequencies were CYP2C19*1 (64.33%), *2 (31.06%) and *3 (4.61%). The major prevalent genotype combinations were CYP2C19 *1/*1 (41.73%) and *1/*2 (39.65%). The distribution of CYP2C19 phenotypes was divided into extensive metabolizers (EM) (41.73%), intermediate metabolizers (IM) (45.21%), and poor metabolizers (PM) (13.06%). In the Hakka population, frequencies of the CYP2C19 *2 and *3 variants were observed to be close to those previously identified in Chinese and several other Asian populations.
CONCLUSIONS: Our study is the first to report on CYP2C19 polymorphisms in the Hakka population, and may help to optimize pharmacotherapy effectiveness by providing personalized medicine to this ethnic group in the near future.

Keywords: China, Pharmacogenetics, Polymorphism, Genetic



Back